Nicotine & Tobacco Research Nicotine & Tobacco Research Advance Access published July 9, 2010 Original Investigation The use of snus for quitting smoking compared with medicinal products Karl Erik Lund, Ph.D.,1 Ann McNeill, Ph.D.,2 & Janne Scheffels, Ph.D.1
1 Norwegian Institute for Alcohol and Drug Research, Oslo, Norway2 UK Centre for Tobacco Control Studies, Division of Epidemiology & Public Health, University of Nottingham, Nottingham, UK
Corresponding Author: Karl Erik Lund, Ph.D., Norwegian Institute for Alcohol and Drug Research, PO Box 565 Sentrum, 0105 Oslo, Norway. Telephone: +47-91-73-37-58; Fax: +47-22-34-04-01; E-mail: kel@sirus.no
Received April 7, 2010; accepted June 3, 2010
A consistent finding in Swedish (Gilljam &
Abstract
and Norwegian ; ) observational studies is
Introduction: Given there are few experimental studies com-
that the quit rate for smoking is higher for snus users than for
paring the effects of snus and medicinal products for quitting
smokers who have no experience of use of snus. To our knowl-
smoking, self-reports from smokers who have used different
edge, other than a few small pilot studies
methods for quitting smoking can be informative. Methods: Fourteen thousand seven hundred and forty-four controlled trials (RCT) or experimental studies have been car-
Norwegian men aged between 20 and 50 years were selected at
ried out to compare the effect of snus and medicinal nicotine
random from a national representative web panel and sent a
products on quitting smoking. In the absence of such studies,
questionnaire by E-mail. Of the 7,170 (48.6%) who responded,
self-reported data have been used to shed light on the effect of
there were 1,775 former and 1,808 current smokers. They were
the different methods for quitting smoking (Ramström &
asked about the method they used and the outcome of their last
Foulds), although the degree of evidence is lower.
We examined the self-reported outcome of smokers’
Results: In a regression model in which education, number of attempts to quit smoking using the following methods of quitting:
previous attempts to quit smoking, perception of risk, and age
snus, nicotine patches, nicotine chewing gum, bupropion
were controlled for, the odds ratio (OR) for reporting total absti-
nence at the time of the survey was significantly higher for those who had used varenicline (OR = 4.95, p < .006) and snus (OR =
2.68, p < .001) compared with those who had used nicotine chewing gum (reference OR = 1). For smokers who reported
An invitation to participate in the survey was sent by E-mail to
that they had tried to quit with the help of snus, 62.4% reported
14,744 men aged 20–50 years in 2007, who had been randomly
that they still used snus at the time of the survey either daily
selected from a web panel of 62,000 Norwegians administrated by
(43.8%) or occasionally (18.6%). The proportion who still used
the international research agency Synovate. People were recruited
medicinal nicotine products at the time of the survey was 9.5%.
to this web panel when they had participated in previous nation-ally representative population surveys, carried out by telephone,
Discussion: Compared with medicinal nicotine products, snus post, or personal interview and had agreed to receive future invi-
and varenicline increased the probability of quitting smoking
tations to participate in surveys by E-mail. Self-recruitment to the
completely, but snus seemed to maintain nicotine dependence.
panel was not possible. Of those invited to participate, 7,170 men (48.6%) responded. No significant differences at the 5% level were detected in the distributions of the national population and
Introduction
the respondents when compared by age and region.
In general, the Nordic health authorities do not recommend use
The final sample consisted of 1,775 former daily or occa-
of snus as a method for quitting smoking
sional smokers and 1,808 current daily or occasional smokers, a
total of 3,583 people. Former smokers and smokers who had
recently agreed that health care personnel can recommend snus
tried to quit were asked “Did you use some of these methods
in individual cases of inveterate smokers (
when you last tried to quit smoking (multiple answers possi-
). However, studies have shown that snus is the
ble)?” Response categories were nicotine gum, nicotine patch,
preferred method for quitting among male smokers in Sweden
snus, inhaler, Zyban, Champix, called the quitline, attended
and Norway, and this method is also used by an increasing
a course or consulted health personnel, and read brochures/
self-help material (Table 1). The association between using
doi: 10.1093/ntr/ntq105 The Author 2010. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Use of snus for quitting smoking Table 1. Percentage using different methods for quitting smoking on last quit attempt among ever smokers, former smokers, and current smokers (multiple choice of methods possible), and ratio of former/current smokers for each quit-smoking method
different methods was measured by Pearson’s coefficients that
respondents who had quit smoking completely were excluded
can range in value from −1 (a perfect negative relationship)
to +1 (a perfect positive relationship). Use of one method pre-dicts the use of another method if correlation between the two
Perception of risk was measured using the question “On a
was positive and significantly different from 0 (no relationship).
scale from 1 to 7, where 1 is ‘not dangerous’ and 7 is ‘very dan-
If use of one method reduced the probability to take up an ad-
gerous’, how dangerous to health do you believe use of cigarettes
ditional method, the correlation had a negative sign (Table 2).
is?” For use in the regression analysis, the scores were grouped
Correlation coefficients significant at the .05 level were identi-
into three values by splitting the sample in “low” (range 1–5),
fied with a single asterisk, and those significant at the .01 level
“medium” (6), and “high score” (7). Scores for age and number
of attempts to quit were grouped into three values by splitting the sample at the values closest to the 33rd and 66th percentile.
The respondents were also asked “What was the result of
your latest attempt to quit smoking?” The response categories were quit smoking completely, greatly reduced their cigarette
consumption, reduced their cigarette consumption somewhat,
and smoked about the same as before. The odds ratios (ORs)
Snus was the most common method for quitting smoking, fol-
for reporting “quit smoking completely” (table 3), and then in
lowed by nicotine chewing gum, self-help materials, and nico-
another model “greatly reduced cigarette consumption” (table 4),
tine patches (Table 1). The proportion of current smokers (and
were calculated using logistic regression controlling for method
thus unsuccessful quitters) was greater than the proportion of
for quitting, length of highest completed education, number
former smokers (and thus successful quitters) for all methods
of previous attempts to quit, risk perception, and age. Only
for quitting smoking. However, the ratio of successful to unsuc-
people who reported using only one of nicotine chewing gum,
cessful quitters was higher for snus than for the other methods
nicotine patches, snus, bupropion, or varenicline were included
in the regression analysis. However, these respondents could have used other methods for quitting smoking, such as self-
Just under half (n = 1,727, 48.2%) of current or former
help materials, a telephone helpline for smoking, or consulta-
smokers reported that they had used at least one of the nine
tion with health care personnel. In the model for Table 4,
specified methods to try to quit smoking on their last attempt.
Table 2. Relationship between methods of quitting. Bivariate correlations (Pearson) with asterisks identifying significant associations Note. **Correlation at .01 (two tailed), *correlation at .05 (two tailed). Nicotine & Tobacco Research Table 3. Percentage (bivariate) and Table 4. Percentage (bivariate) and adjusted odds ratios (AORs) for having quit adjusted odds ratio (AOR) for having greatly smoking completely at the last attempt for reduced cigarette consumption at the last men aged 20–50 years. Odds ratio is attempt for men aged 20-50 years. OR is adjusted for method of quitting, length of adjusted for method of quitting, length of education, number of previous attempts to education, number of previous attempts to quit, risk perception, and age group quit, risk perception and age group Discussion
While use of a conventional method, recommended by the authorities, consistently increased the probability for also using
The study has shown that snus is the preferred method for quit-
one of the other recommended methods, use of snus was sig-
ting smoking for men in the age group 20–50 years. In addition,
nificantly negatively correlated with all the other methods of
those using snus were more likely to have quit smoking com-
pletely or considerably reduced their cigarette smoking than users of medicinal smoking cessation products. This is the case
The OR of reporting total abstinence at the time of the survey,
despite the fact that users of medicinal nicotine products had a
when controlling for the other factors, was significantly higher
greater tendency to use additional methods for quitting smoking,
for use of snus only than for use of one of any of the other methods
which would normally increase the probability of a positive re-
for quitting. Fewer previous attempts to quit, concern about the
sult. Use of snus seemed to be a more solitary method and might
health risks, and increasing age also increased the probability for
appear convenient for smokers who for some reason do not
having quit smoking (Table 3). In a model predicting “greatly
want to make use of the nicotine replacement therapy medicinal
reduced cigarette consumption,” the significant predictors were
products. However, the survey indicates that use of snus as a
reduced to use of snus as the method for quitting and length of
method for quitting smoking may result in continued use after
the attempt to quit. Such prolonged use of snus not only oc-curred among those who quit smoking or who greatly reduced
Of those smokers who reported that they had tried to quit
their cigarette consumption but also among those who man-
by using snus, 62.4% reported that they still used snus at the
aged to change their cigarette consumption to a lesser extent.
time of the survey, either daily (43.8%) or occasionally (18.6%). People who had quit completely or greatly reduced their ciga-rette consumption with the help of snus were more likely to use
Limitations
snus on a daily basis than people whose attempt to quit had
The study has weaknesses common to other cross-sectional
resulted in less change in cigarette consumption. In compari-
surveys using self-reported data. In contrast to an RCT, our study
son, only 9.5% who had used nicotine chewing gum or nicotine
design does not ensure comparability of different groups. Thus,
patches at the last attempt to quit were still using these medicinal
the possibility cannot be excluded that there are differences
nicotine products at the time of the survey (Table 5).
between the groups with regard to variables that can influence
Use of snus for quitting smoking Table 5. Proportion of men 20–50 years old who used snus or medicinal nicotine products to quit smoking who were using these products at the time of the survey
Outcome of last quit attempt Quitted smoking completely
Great reduction in cigarette consumption
the outcome of an attempt to quit smoking, such as smoking
), and the price is only a bit lower than
intensity, smoking history, degree of nicotine dependence, and
the price of cigarettes. Some of the reasons why snus still has
strength of intention to quit smoking. We have controlled for
greater potential for use than medicinal nicotine products are
some variables (age, number of previous attempts to quit smok-
that the nicotine dose is almost the same as for cigarettes
ing, perception of risk, and education), which compensate to
some extent—but not fully—for the absence of randomization.
choice of brand, aesthetic rituals of use, and visibility can repre-
However, the current kind of observational studies are superior
sent social positioning and self presentation (
to RCT when it comes to evaluate effectiveness under real life
). Use of snus can thus—in contrast to nicotine chewing
conditions for different smoking cessation methods.
gum and nicotine patches—have functions that are identical to those offered by cigarettes. In addition, snus, similar to ciga-
Another weakness is that we do not have data about the
rettes, tastes of tobacco and thus has a sensory effect that me-
length of time from the attempt to quit smoking to the time of
dicinal nicotine products perhaps lack. This suggests that snus is
the survey. We cannot exclude the possibility that there are
the only nicotine product on the Norwegian market that can
systematic differences between smokers who use the different
compete in popularity with cigarettes The like-
methods, with regard to length of time between attempts to quit
ability of snus implies that the impact on smoking cessation at
smoking or recall of quit attempts, but there is not any obvious
the population level (effectiveness) will be higher than medicinal
reason that this would be the case. Respondents with an over-
nicotine products. This would be the case even if, hypothetically,
average interest in smoking cessation might be overrepresented
future RCTs should moderate our results in finding that use of
in studies like this, but again, we find no reason that this interest
snus results in no increase in rates of abstinence (efficacy).
should be systematically imbalanced between users of the differ-ent methods. Finally, the outcomes studied here are self-reports,
The higher rates of snus use among those using snus on
and these are not validated with biochemical markers. Thus,
their last quit attempt may be an indication that use of snus
there is a need to carry out experimental studies that can
when quitting smoking contributes to maintaining dependence
on nicotine and that the method can result in dual use for those whose attempt to quit has been unsuccessful. Against this back-
Use of snus for smoking cessation
ground, advice against using snus as a method for quitting smoking as a general strategy seems to be sensible. However, the
rather than medicinal products
method could be particularly relevant for intransigent smokers
who are seriously addicted to nicotine and who have been
), our study shows that medicinal nicotine products
unsuccessful in quitting using conventional methods. For these
are not the most popular method chosen by Norwegian smok-
people, as for all other smokers, nicotine uptake from snus
ers to quit smoking. This is the case even though the pharma-
instead of from cigarettes has the potential for reducing harm by
ceutical companies have, for nearly 25 years, widely advertised
at least 90% (It should also be emphasized
these products as effective stop-smoking aids, that they are
that a substantial fraction (37.6%) of those using snus as
widely accessible over-the-counter products, and given recom-
a method for quitting in fact ended up tobacco free, as also
mendations by the health authorities. The low utilization is re-
lated to, among other things, the fact that they are deliberately made unattractive in order to avoid misuse and that they give a
A possible negative consequence of allowing use of snus as a
much lower dose of nicotine than cigarettes. The first genera-
method for quitting among inveterate smokers is that the method
tion of nicotine chewing gum was made with an unpleasant
would not only be used by these highly nicotine-dependent
taste in order for it to be authorized for sale but is now on the
smokers. A partial approval of snus as a potential quit smoking
market with flavors of mint, fruit, or liquorice.
method might result in many smokers, who otherwise would have been able to quit using tobacco completely, would be
With regard to snus, its effect on quitting smoking is not
recruited into prolonged nicotine dependence from snus.
In this connection, a relevant challenge for further research is to
find out whether transition from cigarettes to snus will increase
the health authorities advise against its use, the percep-
or decrease the risk of future relapse to smoking as compared
tion of health risks are exaggerated in the population (
Nicotine & Tobacco Research Why is snus more effective than References medicinal nicotine products? Of 100 people who try to quit smoking, about 95 will relapse
Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B. Jr.,
within 6 months without using medicinal nicotine products.
Gong, J., et al. (2008). Varenicline versus transdermal nicotine
At best, only five more people will quit smoking completely by
patch for smoking cessation: Results from a randomised open
label trial. Thorax, 63, 717–724.
). It has been calculated that availability of nonpre-
Cummings, K. M., & Hyland, A. (2005). Impact of nicotine
scription medicinal nicotine products has had no measurable ef-
replacement therapy on smoking behavior. Annual Review of
fect on the quit rate for smoking in the United States (
Public Health, 26, 583–599.
. This is primarily because so few smokers use these products but also because the effect of medicinal nicotine
Etter, J. F., & Stapleton, J. A. (2006). Nicotine replacement ther-
products is quite low when measured after 12 months (
apy for long-term smoking cessation: A meta-analysis. Tobacco Control, 15, 280–285.
(). So snus does not need to have a very
Gilljam, H., & Galanti, M. R. (2003). Role of snus (oral moist
great effect on the quit rate in order to produce better results
snuff) in smoking cessation and smoking reduction in Sweden.
than medicinal nicotine products. Studies have shown that
Addiction, 98, 1183–1189.
varenicline (Champix) has a much better effect than medicinal nicotine products ()—which our study has
Hatsukami, D. K., Ebbert, J. O., Feuer, R. M., Stepanov, I., &
also shown—but this product is only available on prescription,
Hecht, S. S. (2007). Changing smokeless tobacco products. New
is relatively new and not widely used, and will thus not have a
tobacco-delivery systems. American Journal of Preventive Medi-
great effect on the quit rate at the population level unless there
cine, 33, S368–S378.
Helgason, A. R., Tomson, T., Lund, K. E., Galanti, R., Ahnve, S., &
We must assume that the most important reason why snus is
Gilliam, H. (2004). Factors related to abstinence in a telephone
reported to be more effective for quitting smoking than medicinal
helpline for smoking cessation. European Journal of Public
nicotine products is that it provides a high enough dose of nico-
Health, 14, 306–310.
tine so that it feels satisfying for smokers ).
Holm, L. E., Fisker, J., Larsen, B. I., Puska, P., & Halldórsson, M. (2009). Snus does not save lives: Quitting smoking does!
Since snus contains carcinogenic substances and increases
Tobacco Control, 18, 250–251.
the risk of cancer of the esophagus and the pancreas—though lower than for smoking (would be
Hughes, J. R., Shiffman, S., Callas, P., & Zhang, J. (2003).
ethical objections to carrying out an RCT. An alternative design
A meta-analysis of the efficacy of over-the-counter nicotine
would be to divide people who call the quitline according to
replacement. Tobacco Control, 12, 21–27.
method for quitting smoking, to measure other variables that
Levy, D. T., Mumford, E. A., Cummings, K. M., Gilpin, E. A.,
have significance for quitting smoking at the baseline, and then
Giovino, G., Hyland, A., et al. (2004). The relative risks of a low-
to follow up these people prospectively, as has been done in
nitrosamine smokeless tobacco product compared with smoking
cigarettes: Estimates of a panel of experts. Cancer Epidemiology,
The study indicates that use of varenicline and snus increases
Biomarkers & Prevention, 13, 2035–2042.
the probability of a positive outcome of an attempt to quit
Lund, K. E. (2009a). A tobacco-free society or tobacco harm re-
smoking compared with medicinal nicotine products. This is
duction? Which objective is best for the remaining smokers in
the case despite the fact that users of medicinal nicotine products
Scandinavia? SIRUS-report 6/2009. Oslo: Norwegian Institute
have a greater tendency than snus users to use other additional
methods that have a positive effect on quitting smoking. Further studies should be carried out with a design that can provide better
Lund, K. E. (2009b). The role of snus in the decline of smoking in
evidence. Prolonged use of snus was also widespread among
Norway. [Online presentation]. Mumbai, India: 14th World Con-
smokers who made unsuccessful attempts to quit smoking. As a
ference on Tobacco or Health. Retrieved May 26, 2010, from http
method for quitting smoking, snus should only be considered
://www.14twctoh.org/speaker.htm?spkname=Karl E Lund&fdr=
for seriously nicotine-dependent smokers who have previously
abstract/Trident/09-March/1530–1630 hrs/Rooftop&spk=lund
been unsuccessful with other methods.
&txt=1&vid=2&presname=The role of snus in the decline of smoking in Norway
Mendoza-Baumgart, M. I., Tulunay, O. E., Hecht, S. S., Zhang, Y.,
Murphy, S., Le, C., et al. (2007). Pilot study on lower nitro-samine smokeless tobacco products compared with medicinal
The study was supported by The Norwegian Directorate of
nicotine. Nicotine & Tobacco Research, 12, 1309–1323.
Health and by the Norwegian Research Council project no. 190443 “Tobacco and the social inequality gap.”
Nordby, K., & Wood, R. T. A. (2008). A grounded theory of snuff-dipping behavior in a Norwegian population. Addiction Research and Theory, 16, 5–22. Declaration of Interests Norwegian Directorate of Health. Anbefaler røykeslutt uten snus (Quit smoking without the use of snus). Oslo, Norway:
Norweigian Directorate of Health. Retrieved May 26, 2010, from
Use of snus for quitting smoking
http://www.helsedirektoratet.no/tobakk/aktuelt/anbefaler_r_
Scientific Committee on Emerging and Newly Identified Health
Risks. (2008). Health effects of smokeless tobacco products. Brussels, Belgium: Health & Consumer Protection DG, European
Øverland, S., Hetland, J., & Aarø, L. E. (2008). Relative harm
of snus and cigarettes: What do Norwegian adolescents say? Tobacco Control, 17, 422–425.
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T.
Ramström, L. M., & Foulds, J. (2006). Role of snus in initiation
(2008). Nicotine replacement therapy for smoking cessation.
and cessation of tobacco smoking in Sweden. Tobacco Control,
Cochrane Database of Systematic Reviews, 1, CD000146.
Stenbeck, M., Hagquist, C., & Rosén, M. (2009). The association
Scheffels, J., & Lund, K. E. (2009). Snus as a strategy for smoking
of snus and smoking behavior: A cohort analysis of Swedish
cessation. [Online presentation]. Mumbai, India: 14th World
males in the 1990s. Addiction, 1004, 1579–1585.
Conference on Tobacco or Health. Retrieved from http://www .14twctoh.org/speaker.htm?spkname=Janne Scheffels&fdr=abstract
Tilashalski, K., Rodu, B., & Cole, P. (1998). A pilot study of
/Trident/09-March/1530–1630 hrs/Rooftop&spk=scheffels&txt=1
smokeless tobacco in smoking cessation. American Journal of
&vid=2&presname=Snus as smoking cessation strategy
Medicine, 104, 456–458.
Form 10-3e Academic Year 2010-11 Drug-Testing Consent − NCAA Division II Sign and return to your director of athletics. Due date: In sports in which the Association conducts year-round drug testing, at the time your intercollegiate squad first reports for practice or the first day of competition (whichever date occurs first). Required by: NCAA Constitution 3.2.4.6 and NCA
PATIENT: RESULTS: LAB INFO: Patient: John Doe (Primary Care) Phenotype: Genotype: Collected: Received: Reported: Patient's genotype will never change. Login to YouScript to identify possible interaction risks when making medication changes. Advisory Note to Treating Practitioner: The prescribing suggestions below are based on standard doses of